Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Genomic Health Reports Recommendation of Oncotype DX(R) in National Comprehensive Cancer Network Guidelines
January 15th, 2008
Genomic Health, Inc. (NASDAQ:GHDX) reported that the company's Oncotype DX(R) breast cancer assay, used to predict the likelihood of disease recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients, has been included in the National Comprehensive Cancer Network (NCCN) 2008 Breast Cancer Treatment Guidelines. Oncotype DX is the only multi-gene expression assay to be recommended by NCCN, an alliance of 21 world-leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. These guidelines were published online at http://www.nccn.org/. "We are pleased that NCCN, a...
Source: Cancer Weekly (2008-01-15)
|
